While there is evidence that HLA-I homozygosity is associated with shorter survival among NSCLC patients treated with checkpoint inhibitors in the first- or second-line inhibitors [10,11], this association seems to be more pronounced among patients with a PD-L1 expression of 50% or more of cancer cells [10]. Here, CD274 is linked to cancer.